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ABSTRACT
Following the ﬁrst outbreaks of legionnaire’s disease, erythromycin emerged as the treatment of choice
without the foundation of rigorous clinical trials. The number of therapeutic failures with erythromycin,
as well as the side-effects and drug interactions, led to the consideration of other drugs such as the new
macrolides and quinolones for the treatment of legionnaire’s disease in the 1990s. In this article, 19
studies in in-vitro intracellular models and seven animal studies that compared macrolides to
quinolones were reviewed. Quinolones were found to have greater activity in intracellular models and
improved efﬁcacy in animal models compared with macrolides. No randomised trials comparing the
clinical efﬁcacy of the new macrolides and new quinolones have ever been performed. Three
observational studies totalling 458 patients with legionnaire’s disease have compared the clinical
efﬁcacy of macrolides (not including azithromycin) and quinolones (mainly levoﬂoxacin). The results
suggested that quinolones may produce a superior clinical response compared with the macrolides
(erythromycin and clarithromycin) with regard to defervescence, complications, and length of hospital
stay. Little data exist for direct comparison of quinolones and azithromycin.
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INTRODUCTION
Controlled trials of antibiotics for the treatment of
legionnaire’s disease have never been conducted
for a number of reasons. In the American Legion
outbreak of 1976, patients treated with erythro-
mycin and tetracycline fared better than those
treated with other antibiotics (especially b-lactam
antibiotics) [1]. Subsequent experience with hos-
pital-acquired legionnaire’s disease also sugges-
ted the superiority of erythromycin over other
antibiotics [2,3]. Thus, erythromycin emerged as
the drug of choice based on anecdotal experience
[4].
On the other hand, treatment failures with
erythromycin [5–7] led to the empirical practice of
increasing the dose of erythromycin (from 500 mg
to 1 gram four times a day) and the addition of
rifampin; no data were ever generated to support
this practice which soon became commonplace.
Its interaction with the metabolism of numerous
drugs, as well as the adverse effects of ﬂuid
overload and ototoxicity because of high doses,
also became problematic. In the 1990s the newer
macrolides (azithromycin, clarithromycin, roxith-
romycin) and quinolones were introduced, with
notably greater in-vitro activity than erythromy-
cin. Quinolones were shown to be more active
than any macrolides for Legionella in in-vitro
studies, intracellular models, and animal models,
but it was unclear whether this superiority would
be translated into clinical practice.
The intracellular location of the pathogen
proved to be relevant to the efﬁcacy of the
antibiotic. Speciﬁcally, antibiotics capable of
achieving intracellular concentrations higher than
the MIC were more clinically effective than
antibiotics with poor intracellular penetration
[8]. For example, erythromycin and rifampin
were able to prevent death in guinea pigs inocu-
lated intraperitoneally with large numbers of
Legionella. On the other hand, antibiotics with
poor intracellular presentation (penicillin,
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chlorampheniciol, tetracycline, and gentamicin)
were ineffective in preventing death [9,10]. Thus,
the theoretical basis for the empirical observation
that macrolides, quinolones, tetracyclines, and
rifampin were more likely to be efﬁcacious was
supported by a biological rationale since these
antibiotics achieved relatively high intracellular
penetration.
The recommendation of the use of macrolides
such as azithromycin as preferred therapy was
introduced in the ﬁrst North American consensus
guidelines for empirical therapy of patients with
community-acquired pneumonia [11–13]. Quino-
lones also became widely used for community-
acquired pneumonia because of their activity
against Legionella pneumophila and the spectre of
penicillin-resistant pneumococci [14] (a fear
which is now known to be unjustiﬁed).
SUSCEPTIBILITY TESTING
Dilutional tests of in-vitro susceptibility in agar or
broth have correlated poorly with clinical out-
come since they measure extracellular suscepti-
bility. Thus, intracellular models and animal
studies have supplanted the standard tests for
antimicrobial susceptibility testing. In 19 studies
in in-vitro intracellular models of Legionella sus-
ceptibility, quinolones were consistently more
active than macrolides (Table 1). Likewise, in
seven comparative studies performed in animal
models, quinolones were superior to macrolides
(Table 2).
COMPARATIVE CLINICAL STUDIES
Comparative antibiotic studies have not been
performed because, in the early years following
discovery of legionnaire’s disease, patients were
identiﬁed mainly in outbreaks, making it difﬁcult
to perform a controlled trial. Patients with hospi-
tal-acquired legionnaire’s disease were not stud-
ied because disinfection of the drinking water
reservoir was ethically required upon discovery
of cases; following disinfection, subsequent cases
were unlikely to occur. Nevertheless, three obser-
vational studies have addressed the comparative
efﬁcacy of quinolones and macrolides.
Blazquez et al. [15] conducted an observational,
prospective study of 292 patientswith L. pneumonia
during the Murcia, Spain outbreak. Patients were
stratiﬁed according to the severity of pneumonia in
order to compare those who received macrolides
(n = 65) and those who received levoﬂoxacin
(n = 143). Mykietiuk et al. [16] conducted a pros-
pective, observational series of 1934 consecutive
cases of community-acquired pneumonia in non-
immunocompromised adults [16]. One hundred
and thirty-nine cases of legionnaire’s disease were
diagnosed. Patientswere classiﬁed into twogroups
based on therapy: macrolides (n = 80) or levoﬂ-
oxacin (n = 40) therapy. Sabria et al. [17] conducted
a retrospective observational multicentre study of
legionnaire’s disease that included 76 patientswho
received macrolides and 54 patients who received
ﬂuoroquinolones (50 levoﬂoxacin and four oﬂoxa-
cin).
When the results of all studies were combined:
51.2% (128 ⁄ 250) were smokers [16,17]; 23.6%
(59 ⁄ 250) had chronic pulmonary diseases [16,17];
44.1% (202 ⁄ 458) had no underlying diseases; 6.9%
(32 ⁄ 458) required ICU admission [15–17]. No
signiﬁcant differenceswere found among the three
studies concerning age, sex, cigarette smoking,
chronic lung diseases, and severity of pneumonia
for the two treatment groups (macrolides and
quinolones). Unlike the studies of Garrido and
Mykietiuk, immunosuppressed patients (13%)
and cases of hospital-acquired legionnaire’s dis-
ease (17.6%) were included in the multicentre
study by Sabria` et al. [17]. Forty-ﬁve per cent
(205 ⁄ 458) were diagnosed according to antibody
seroconversion [15,16], 85.1% (390 ⁄ 458) according
to urinary antigen test positivity for L. pneumophila
serogroup 1 [15–17], and 9.3% (43 ⁄ 458) according
to isolation from culture [16].
Time to defervescence was notably shorter in
patients receiving levoﬂoxacin in two studies
[16,17]. The mean time was 97.7 h for patients
receiving macrolides and 66.6 h for those receiv-
ing levoﬂoxacin in the three studies. Length of
hospital stay was signiﬁcantly shorter for patients
treated with levoﬂoxacin in all three studies. The
mean hospital stay for all three studies was
9.0 days for patients receiving macrolides and
6.6 days for the levoﬂoxacin group. Patients
receiving levoﬂoxacin had fewer complications
(8.4%, 20 ⁄ 237), as deﬁned by pleural effusion,
empyema, cavitation, septic shock, and mechani-
chal ventilation, than those receiving macrolides
(18.5%, 41 ⁄ 221) [15–17].
The incidence of treatment-related adverse
events was 23.4% (34 ⁄ 145) for patients receiving
macrolides and 12.5% (23 ⁄ 183) for those receiving
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levoﬂoxacin. Phlebitis was the most frequent
adverse effect, but none of the affected patients
had to discontinue the antibiotic.
The delay until the initiation of an appropriate
antibiotic treatment was only noted in the Sabria`
study andwas not signiﬁcantly different in the two
groups (78.5 h for the macrolide group vs. 92.7 h
for the quinolone group). The time in which
intravenous administration of antibiotics was
switched to oral therapy was signiﬁcantly shorter
in the quinolone group (3.8 days in the quinolone
group vs. 5.3 days in the macrolide group) [16,17].
The overall mortality was 4.5% (10 ⁄ 221) for the
macrolide group and 2.1% (5 ⁄ 237) for the levoﬂ-
oxacin group. In summary, the results from these
three observational studies [15–17], totalling 458
patients with legionnaire’s disease, suggested that
levoﬂoxacin may produce a superior clinical
response compared with macrolides for end-
points of defervescence and hospital stay
(Table 3); however, the mortality rate was similar.
Limitations
As mentioned, none of the above studies were
randomised trials, so biases could easily have
been present. Multiple subgroup analysis was
suggested as a ﬂaw in the statistical analysis of
Table 1. Activity of quinolones vs. macrolides in intracellular models
References Cellular Model Legionella sp. ⁄ serogroups Comparative activity Comment
Fitzgeorge,1985 [27] Guinea pig pulmonary
alveolar macrophages
Lp Levo > Ery
Havlichek, 1987 [28] Human monocytes Lp serogroup 1 Cipro > Amﬂo > Cino> Enox > Roso > Ery
Fitzgeorge, 1988 [29] Guinea pig pulmonary
alveolar macrophages
Lp serogroup 1 Oﬂox > Cipro > Ery
Edelstein, 1989 [30] Guinea pig pulmonary
alveolar macrophages
L.spp. WIN57273, Cipro and Ery all
inhibited growth of Lp at concentrations
of 1 mg ⁄L, but only WIN 57273 prevented
regrowth or killed Lp after removal
of extracellular antimicrobial agent.
Edelstein, 1991 [31] Guinea pig pulmonary
alveolar macrophages
Lp Azi and Cipro were both bactericidal
but Ery was bacteriostatic
Kitsukawa, 1991 [32] Guinea pig pulmonary
alveolar macrophages
Lp AT-4140 > Roxi > Oﬂo = Cipro > Ery
Edelstein, 1996 [33] Guinea pig pulmonary
alveolar macrophages
Lp serogroup 1,4,6,9;
L. dumofﬁi serogroup 1,
L. micdadei, L. longbeachae,
L. bozemanii serogroup 2
1) Levo showed similar activity to Oﬂox
(2) Levo was slightly less active than Cipro
(3) Levo and Oﬂox were more active than Ery
Levo and Oﬂox showed
a more prolonged PAE
than Ery
Walz, 1997 [34] J774 macrophage Lp BAY Y 3118 and Clina > Cipro > Ery
Smith, 1997 [35] Human mononuclear
phagocytes
L.p serogroup 1 Levo and Ery produced effective inhibition
on Lp. The delay of regrowth with Ery
was < 30 min The delay of regrowth
with Levo was > 72 h
Baltch, 1998 [36] Human monocytes Lp serogroup 1 Levo > Ery After removal of Levo from
human monocytes,
the continued suppression
of Lp was greater than that for Ery
Stout, 1998 [37] HL-60 cell line Lp, serogroups 1,2,3,4,5,6;
L. micdadei, L. bozemanii,
serogroup 1, L. jordanis
Levo > Cipro > Oﬂox > Ery All quinolones were more potent
against. L. micdadei and
L. bozemanii when compared to Lp
Stout, 1998 [38] HL-60 Lp, serogroup 1, L. micdadei,
L. bozemanii
Azi > Clari > Roxitho >
Quinupristin ⁄dalfo > Ery > Diritho
Edelstein, 1999 [39] Guinea pig pulmonary
alveolar macrophages
LP serogroup 1 Levo > Clari = Ery Clarithro and Ery were
bacteriostatic Levo was bactericidal
Edelstein, 2001 [40] Guinea pig pulmonary
alveolar macrophages
Lp Levo = Gemi = Azithro and > Ery Ery was bacteriostatic. Levo, Gemi
and Azithro were bactericidal
Baltch, 2005 [41] derived macrophages Human monocyte Lp, L. micdadei L. micdadei: Gemi > Q
(Levo, Gati, Moxi) > Ery Lp: Moxi > Q
(Gemi, Levo, Gati) > Ery
Baltch, 2005 [41] Human monocytes Lp serogroup 1, L. micdadei Gemi, Levo, Gati and moxi had similar
activities against Lp and L. micdadei
at 10x and > Ery
At 24 h, Moxi > Gemi, Levo, Gati
against Lp, while Gemi > than
the other quinolones against
L. micdadei. The PAE of Gemi
against Lp was dose dependent
Stout, 2005 [42] HL-60 L. micdadei,
L. dumofﬁi,
L. longbeachae, L. feeleii
L. bozmanii
Lp, serogroups 1–15 1) Q > Ketolides > M
(2) Levo > Moxi > Gemi > Grepa > Cipro >
Trova > Ery (3) Ketolides > Azi > Clari > Ery
Stout, 2005 [42] HL-60 cell line Lp serogroup 1 Azithro > Ery Levo > Moxi > Gemi >
Grepa > Cipro > Trova > Ery
Tano, 2005 [43] HEp-2 cells Glass chamber Lp serogroup 1 Moxi > Ery
Lp, Legionella pneumophila; Azi, Azithromycin; Clari , Clarithromycin; Roxi, Roxithromycin; Ery, Erytromycin; Levo, Levoﬂoxacin; Moxi, Moxiﬂoxacin;
Cipro, Ciproﬂoxacin; Clina, Clinaﬂoxacin; Grepa, Grepaﬂoxacin; Gemi, Gemiﬂoxacin; Oﬂox, Oﬂoxacin; Trova, Trovaﬂoxacin; Amﬂo, Amiﬂoxacin; Enox, Enoxacin;
Cino, Cinoxacin; Roso, Rosoxacin; M, Macrolides; Q, Quinolones; PAE, Post antibiotic effect.
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the Blazquez study [19], although we agree with
the authors of the study that the endpoints of
outcome showed a consistent trend toward the
superiority of levoﬂoxacin. Forty-eight patients
in the macrolide group in the Mykietiuk study
also received rifampicin but these patients were
not analysed separately, although it would seem
that this inclusion should not lead to a bias
against macrolides. The doses of quinolones used
in the three studies were not controlled. The
starting doses of levoﬂoacin until defervescence
were higher (500 mg every 12 h) in the Sabria`
study than the standard doses usually recom-
mended (500 mg once a day). Treatment failures
using low doses of oﬂoxacin [20] or ciproﬂoxacin
[21,22] in legionnaire’s disease have been
described.
A more severe limitation, in our opinion, was
that the title of each of the three articles used the
encompassing term ‘macrolides’. Clarithromycin
was the predominant macrolide used in treating
the patients with severe pneumonia in the Blaz-
quez study, clarithromycin and erythromycin in
the Mykietiuk study, and erythromycin in the
Sabria` study. Azithromycin was not included in
any systematic comparison; this is pertinent in
that numerous studies have shown that azithro-
mycin is more active than clarithromycin and
erythromycin in intracellular models (Table 1).
And, in one intracellular model [40] and one
animal study [46], azithromycin was comparable
to the quinolones tested. So, the issue of the
superiority of quinolones over azithromycin has
not been directly addressed.
A surprising 0% mortality was the case for 75
patients receiving levoﬂoxacin for legionnaire’s
disease in six clinical trials performed for the US
Food and Drug Administration (FDA) approval of
levoﬂoxacin [18]. This was the largest antibiotic
study ever published of patients with commu-
nity-acquired pneumonia in which legionnaire’s
disease was identiﬁed; not a single death was
recorded.
CONCLUSIONS
The advantages of choosing a quinolone over a
macrolide for treatment of legionnaire’s disease in
immunocompetent patients with community-ac-
quired pneumonia may be a shorter time to
defervescence with a more rapid achievement of
clinical stability, followed by shorter hospital stay.
Reduction in hospital stay of only 1 day can
reduce healthcare costs by a notable amount.









(days) Complications Mortality Adverse Effects
M Q M Q M Q M Q M Q M Q
Sabria`, 2005 [17] 76 54 77.1 48 9.9 7.6 23.6% (18 ⁄ 76) 16.6% (9 ⁄ 54) 7.8% (6 ⁄ 76) 5.5% (3 ⁄ 54) NA NA
Mykietiuk, 2005 [16] 80 40 108 48 10 8 25% (20 ⁄ 80) 25% (10 ⁄ 40) 5% (4 ⁄ 80) 2.5% (1 ⁄ 40) 30% (24 ⁄ 80) 20% (8 ⁄ 40)
Bla´zquez, 2005 [15] 65 143 108 104 7.2 4.4 4.6% (3 ⁄ 65) 0.6% (1 ⁄ 143) 0% (0 ⁄ 65) 0.6% (1 ⁄ 143) 15.3% (10 ⁄ 65) 10.4% (15 ⁄ 143)
Total 221 237 97.7 66.6 9.03 6.6 18.5% (41 ⁄ 221) 8.4% (20 ⁄ 237) 4.5% (10 ⁄ 221) 2.1% (5 ⁄ 237) 23.4% (34 ⁄ 145) 12.5% (23 ⁄ 183)
NA, not available; n, number of patients; M, macrolides; Q, quinolones.
Table 2. Activity of macrolides compared with quinolones in animal models
Reference Antimicrobial Agents Legionella Animal ⁄Model
Outcome Survival
Macrolide Quinolone
Saito, 1986 [44] Ery vs. Cipro Lp Guinea pig 60% 80%
Saito, 1985 [45] Ery, Josa vs. Oﬂox Lp Guinea pig Ery 60%, Josa 0% 80%
Edelstein, 2001 [46] Azithro vs. Gemi, Levo Lp Guinea pig 100% Gemi 100%, Levo 100%
Garcı´adeLomas, 1998 [47] Ery vs. Trova Lp Guinea pig 90% 100%
Dormon, 1986 [48] Ery vs. Peﬂo Lp Guinea pig Mortality was signiﬁcantly
lower for quinolones
Edelstein, 1990 [49] Ery vs. Spar Lp Guinea pig No differences in mortality
but lung cultures from survivors
were signiﬁcantly more frequently
positive for Lp in the Ery-treated animals
Tzianabos, 1989 [50] Ery vs. Cipro Lp, serogroup 1 Hen’s eggs Quinolones were more effective in
reducing the incidence of lesions
and for prolonging embryo viability
Azithro, Azithromycin; Levo, Levoﬂoxacin; Cipro, Ciproﬂoxacin; Oﬂox, Oﬂoxacin; Ery, Erythromycin; Peﬂo, Peﬂoxacin; Gemi, Gemiﬂoxacin; Spar, Sparﬂoxacin; Josa,
Josamycin; Trova, Trovaﬂoxacin.
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Until deﬁnitive studies are performed, how
should the clinician manage patients? Based on
data from intracellular susceptibility tests,
animal studies and observational studies, we
suggest that quinolones might warrant prefer-
ence over macrolides in compromised hosts with
severe infections who are critically ill. Respirat-
ory failure, hospital-acquisition, advanced
cancer, immunosuppressive chemotherapy and
HIV infection are poor prognostic factors for
legionnaire’s disease; mortality rates in these
subsets of patients are notably higher (> 20%)
[23–26]. In these cases, a more aggressive thera-
peutic approach might be prudent so as to
maximize outcome.
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